Despite increasing recognition of misophonia, there are currently no evidence-based treatments to help those who are suffering. Therefore, the primary purpose of this study is to assess the acceptability, feasibility, and preliminary efficacy of a treatment for misophonia. This study will be conducted in two phases. In the Phase 1, participants will receive a treatment the investigators believe can help manage symptoms of misophonia: The Unified Protocol. This treatment uses evidence-based psychological principles (e.g., managing attention or behavior) in a flexible manner and will focus on developing skills to help reduce the distress and impairment associated with Misophonia. After treatment, patients will provide feedback about their experience. The investigators will use this feedback to revise the treatment as indicated. In Phase 2, participants will receive the revised treatment and provide feedback on their experience. Throughout treatment in either phase, participants will provide daily and weekly information about their symptoms. The aims of this study are (1) to explore the acceptability and feasibility of the Unified Protocol for individuals who experience Misophonia and (2) to examine whether this treatment helps reduce symptoms associated with Misophonia.
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of patients that are satisfied with treatment as measured by the credibility and expectancy questionnaire (CEQ
Timeframe: up to 20 weeks
Number of patients who indicate treatment was acceptable to them (i.e., the treatment approach made sense and was perceived as reasonable)
Timeframe: up to 20 weeks
Number of sessions attended
Timeframe: up to 20 weeks
Number of patients who use mindfulness skills assessed by the Southampton Mindfulness Questionnaire (SMQ)
Timeframe: up to 24 weeks
Number of patients who use cognitive flexibility skills assessed by the UP Cognitive Skills Questionnaire (CSQ)
Timeframe: up to 24 weeks
Number of Patients who use behavior change skills assessed by the UP Behavioral Avoidance Questionnaire (BAQ)
Timeframe: up to 24 weeks
Number of patients who report a decrease in anxiety sensitivity on the Anxiety Sensitivity Index (ASI)
Timeframe: up to 24 weeks
Number of Patients who use behavior change skills assessed by the Brief Experiential Avoidance Questionnaire (BEAQ)
Timeframe: up to 24 weeks
Change in misophonia symptoms as assessed by the Misophonia Questionnaire
Timeframe: assessed weekly, up to 24 weeks
Change in anxiety as measured by the Overall Anxiety Severity and Impairment Scale
Timeframe: assessed weekly, up to 24 weeks
Change in depression as measured by the Overall Depression Severity and Impairment Scale
Timeframe: assessed weekly, up to 24 weeks
Change in anger as measured by the PANAS Hostility Scale
Timeframe: assessed weekly, up to 24 weeks